Moderna Raises 2026 Revenue Growth Outlook to 15%–25%

Moderna raised its full-year 2026 revenue growth outlook to 15% to 25% in its third quarter results released November 6, 2026, well above the up-to-10% growth it had previously reiterated. Its GAAP operating expense outlook improved by about $0.2 billion. Its second-quarter filing expected about 55% of second-half revenue in the third quarter.